期刊文献+

反相高效液相色谱法同时测定人血浆中替米沙坦、氢氯噻嗪含量 被引量:7

Simultaneous Determination of Telmisartan and Hydrochlorothiazide in Human Plasma by RP-HPLC
下载PDF
导出
摘要 目的建立可同时检测人血浆中替米沙坦、氢氯噻嗪含量的反相高效液相色谱方法。方法色谱条件:色谱柱为ZorbaxsoA Extend-C18(4.6mm×150mm,5μm);流动相为乙腈-四丁基氢氧化铵磷酸盐缓冲液(24:76);流速:1.0mL·min^-1;检测波长:230nm(替米沙坦),272nm(氢氯噻嗪);柱温:20℃。结果本法替米沙坦的线性范围为3l.8~l591.2μg·L^-1,r=0.9994.方法回收率为98.68%,RSD=3.09%,最低检测质量浓度为20μg·L^-1,氢氯噻嗪的线性范围为30~240μg·L^-1,r=0.9991.方法回收率为100.32%,RSD=5.11%,最低检测质量浓度为20μg·L^-1结论本法可以同时测定血浆中替米沙坦和氢氯噻嗪的浓度,具有样品处理简单、方法稳定、有较好的实用性,易于开展药动学及药效学研究。 OBJECTIVE To establish a method for simultaneous determination of telmisartan and hydrochlorothiazide in human plasma. METHODS The concentrations of telmisartan and HCTZ were analysed on a Zorbax 80A Extend -C18 (4.6 mm×150 mm,5 μm) column with a mobile phase consisting of tetrabutylammonium hydroxide phosphate buffer solution ( pH 2.26 ) -acetonitrile (76: 24 ) at a flow rate of 1 mL · min^-1, the wavelengthes were 230 and 272 nm, respectively. RESULTS The calibration curve of TMST was linear with the range of 31.8 - 1 591.2 μg · L^-1. The minimum eoncentration was 20 μg · L^-1. The calibration curve of hydrochlo- rothiazide was linear with the range of 30 - 240 μg · L^-1. The minimum concentration was 20 μg · L^-1. CONCLUSION It is a rapid, reproducible method. Clinical application demonstrated that this method was practical and it can be completely used in the study of pharmacokinetics and pharmacodynamics.
出处 《中国药学杂志》 CAS CSCD 北大核心 2007年第19期1496-1498,共3页 Chinese Pharmaceutical Journal
关键词 高效液相色谱法 替米沙坦 氢氯噻嗪 血浆浓度 RP-HPI,C telmisartan hydrochlorothiazide plasma concentration
  • 相关文献

参考文献7

二级参考文献21

  • 1赵飞浪,罗楠,袁倚盛,王平.正相高效液相色谱法测定人血浆中的氢氯噻嗪及药动学研究[J].中国药学杂志,1996,31(8):482-484. 被引量:15
  • 2Stangier J,Su CA,Hendriks MG,et al. The effect of telmlsartan on the steady - state pharmacokinetics of digoxin in healthy male volunteers.J Clin PharmacY,2000,40( 121 ) :1373.
  • 3Mcclellan K J, Markham A. Telmisartan.Drugs, 1998,56 (6) : 1039.
  • 4Wienen W, Hauel N,Van meel JCA, et al. Pharmacological characterization of the novel nonpeptide angiotension Ⅱ receptor antagonist,BIBR-277[J]. Br J Pharmacol,1993,110:245-252.
  • 5Stangier J, Schmid J,Turk D, et al. Absorption,metabolish andexcret-Ion of int-ravenously and orally administered [ C14 ] telmisartan in healthy volunteers [J]. J Clin Pharmacol, 2000,40:1338-1346.
  • 6Mcclellan KJ, Markham A. Telmisartan[J]. Drugs, 1998,56(6):1039-1044.
  • 7Stangiet J,Su CA, Hendriks MGC, et al.The effect of telmisartan on the steady state pharmcokinetics of digoxin in healthy male volunteers[J]. J Clin Pharmacol ,2000,40(121) : 1373-1379.
  • 8党--训,药物分析杂志,1991年,11卷,3期,141页
  • 9Sharma A M, Hollander A, Koster J. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease[J]. Clin Nephrol, 2005, 63(4):250-257.
  • 10Michel M C, Bohner H, Koster J, et al. Safety of telmisartan in patients with arterial hypertension:an open-label observational study[J]. Drug Saf,2004, 27(5): 335-344.

共引文献49

同被引文献37

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部